Grifols's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 40.86.
Grifols's Days Inventory for the
three
months ended in Mar. 2026 was 287.12.
Grifols's Days Payable for the
three
months ended in Mar. 2026 was 71.97.
Therefore, Grifols's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 256.01.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Grifols Cash Conversion Cycle Related Terms
Grifols Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Grifols's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRFS vs LLY, JNJ, ABBV: Cash Conversion Cycle Comparison
For the Drug Manufacturers - General subindustry, Grifols's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Grifols's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Grifols's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (GRFS) has a Cash Conversion Cycle of 256.01 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Grifols and its competitors.
Is Grifols' Cash Conversion Cycle too high?
Grifols' current Cash Conversion Cycle is 256.01. The Drug Manufacturers industry median Cash Conversion Cycle is 145.72. Grifols' value of 256.01 is 75.7% above this industry median. Overall, Grifols has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grifols' Cash Conversion Cycle compare to LLY and JNJ?
Grifols' Cash Conversion Cycle of 256.01 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.72. Grifols' value of 256.01 is 75.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.72, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Cash Conversion Cycle of 256.01 is 75.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Cash Conversion Cycle is 256.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Based on GuruFocus' analysis, Grifols (GRFS) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.86, compared to a current price of $7.36 — trading 17% below its estimated fair value. The current Cash Conversion Cycle is 256.01 and 75.7% above the Drug Manufacturers industry median of 145.72. Grifols' overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Grifols (GRFS), the current Cash Conversion Cycle is 256.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (GRFS) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of $7.36 is trading 17% below its estimated GF Value™ of $8.86.
GuruFocus considers Grifols to be Modestly Undervalued.
Key valuation signals for GRFS:
Cash Conversion Cycle: 256.01
GF Value™: $8.86 vs. price of $7.36 (17% below fair value)
Industry Position: 75.7% above the Drug Manufacturers median
No single metric tells the full story. See the GRFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
84GF Score
Get the complete analysis for GRFS
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRFS has been successfully added to your 
